Olfr790, a member of the olfactory receptor family, plays a pivotal role in the detection of odorant molecules. This protein is a G protein-coupled receptor (GPCR), which is a class of membrane proteins known for their involvement in various cellular processes and signal transduction pathways. The activation of GPCRs like Olfr790 typically involves the binding of specific ligands, leading to a conformational change in the receptor. This change triggers the coupling with G proteins, subsequently initiating a cascade of intracellular events. The precise ligands and functional role of Olfr790 in olfaction or other physiological processes remain to be fully elucidated. However, it is well-established that GPCRs, including olfactory receptors, are modulated by the intracellular levels of second messengers like cyclic adenosine monophosphate (cAMP). The activation mechanisms of Olfr790, as with other GPCRs, can be influenced by the cellular context and the presence of various biochemical mediators. One of the key pathways in GPCR regulation is the cAMP pathway. cAMP is a critical second messenger in cellular signaling and is known to regulate a plethora of cellular functions, including GPCR signaling. The production of cAMP is typically regulated by the enzyme adenylate cyclase, which converts ATP to cAMP in response to various stimuli. Once produced, cAMP can activate protein kinase A (PKA), leading to the phosphorylation of various proteins, including GPCRs. This phosphorylation can lead to changes in receptor conformation, altering their sensitivity and responsiveness to ligands. Additionally, cAMP can modulate other signaling cascades that intersect with GPCR pathways, further influencing receptor activity.
Phosphodiesterases (PDEs) play a crucial role in regulating cAMP levels by catalyzing its breakdown. Inhibiting PDEs can therefore lead to increased cAMP levels within the cell, potentially influencing GPCR signaling. Various PDE inhibitors, by elevating cAMP levels, can indirectly modulate the activity of GPCRs, including Olfr790. Such indirect modulation can occur through alterations in receptor phosphorylation status, changes in receptor-ligand interactions, or modifications in receptor coupling with G proteins. Additionally, compounds that directly increase cAMP levels, such as adenylate cyclase activators or β-adrenergic receptor agonists, can also indirectly affect Olfr790 activity. These interactions illustrate the complexity of GPCR regulation and highlight the potential of various chemical compounds to modulate the activity of these receptors indirectly. In summary, Olfr790 activation is a multifaceted process influenced by the interplay of various cellular components and signaling molecules. Understanding the nuances of these interactions and the potential of chemical compounds to modulate GPCR activity is crucial for advancing our knowledge of olfactory receptors and their broader physiological roles.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a synthetic catecholamine, acts as a non-selective agonist for β-adrenergic receptors. It increases intracellular cAMP levels via adenylate cyclase activation. This cAMP surge could indirectly modulate GPCR signaling pathways, including those associated with Olfr790, thus potentially enhancing its activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, leading to increased intracellular cAMP and cGMP levels. The elevated cAMP could indirectly influence Olfr790 activation by modulating the signaling pathways that converge on GPCRs, possibly through alterations in receptor conformation and signaling efficacy. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, an endogenous catecholamine, stimulates both α and β-adrenergic receptors, increasing cAMP levels via adenylate cyclase. This increase in cAMP can indirectly affect GPCR signaling, including pathways related to Olfr790, potentially enhancing its activation through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), leading to increased cAMP levels in cells. Higher cAMP levels could indirectly enhance Olfr790 activity by modulating signaling pathways that intersect with GPCRs, potentially altering receptor dynamics and downstream signaling. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide, a selective PDE3 inhibitor, elevates intracellular cAMP by hindering its breakdown. This cAMP upsurge could indirectly influence Olfr790 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol, a β2-adrenergic receptor agonist, increases intracellular cAMP via adenylate cyclase stimulation. This rise in cAMP might indirectly boost Olfr790 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, raises intracellular cAMP and cGMP levels. Elevated cAMP might indirectly stimulate Olfr790 by influencing signaling pathways associated with GPCRs, potentially affecting receptor conformation and signaling. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, a synthetic catecholamine, acts on β1-adrenergic receptors, increasing cAMP levels. This cAMP elevation could indirectly modulate Olfr790 activity by affecting GPCR-mediated signaling pathways, potentially leading to changes in receptor activation dynamics. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, enhances intracellular cAMP by preventing its degradation. This increase in cAMP could indirectly influence Olfr790 activation by affecting signaling pathways related to GPCRs, potentially modifying receptor responsiveness and signaling efficacy. | ||||||